ISPC

NASD iSpecimen Inc
Nov 20, 2026 · 6:22 AM ET LAST TRADE Market Closed

$0.4900 ↓ -0.0380 (-7.20%) Trading Down from the previous close of $0.5280

YTD change
-95.29%
vs 20-day SMA
-34.50%
vs 200-day SMA
-87.46%

Price ranges

Previous day
$0.4713 $0.5400
open $0.5230 close $0.5280
+$0.0050 (+0.96%)
Today
$0.0000 $0.0000
$0.4900
Past week
$0.4713 $0.6965
from $0.6965 now $0.4900
-$0.2065 (-29.65%)
Past month
$0.4713 $0.9576
from $0.8327 now $0.4900
-$0.3427 (-41.16%)
This year
$0.1005 $10.4040
from $10.4040 now $0.4900
-$9.9140 (-95.29%)

Price & Performance

-2.87 (-84.47%) / 6M

$0.2846$1.46$2.64$3.81May 20Aug 20Nov 19

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 100.0% away from all-time highs of $23,183.9000
  • ISPC is down 95% since the beginning of the year
  • ISPC is down 97% over the past 12 months
  • ISPC is down 41% over the past 1 month
  • 3% of all ISPC investors are betting against ISPC

ISPC reads poor: price sits below both the 20- and 200-day averages, the 12-month move is +25.4%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-1.0258
Earnings momentum N/A Quarterly EPS growth
Quarterly change N/A

Valuation

P/E ratio N/A
Enterprise value $-4191830.0
Beta 1.58

Balance sheet & scale

IncomeN/A
Revenue$603.7K
Cash$5.6M
Debt$227.0
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Market cap $2.8M

iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in 2009 and is headquartered in Woburn, MA.

Competitor comparison

No peer group available for this symbol.

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.